Jennifer Doudna - Johnson Johnson Independent Director
JNJ Stock | MXN 2,485 0.48 0.02% |
Director
Dr. Jennifer A Doudna, Ph.D., is the Independent Director of the Company. She has joined the faculty at University of California, Berkeley, as a Professor of Biochemistry Molecular Biology in 2002. She directs the Innovative Genomics Institute, a joint UC BerkeleyUC San Francisco center, holds the Li Ka Shing Chancellors Professorship in Biomedicine and Health, and is the chair of the Chancellors Advisory Committee on Biology at UC Berkeley. Dr. Doudna is Principal Investigator at the Doudna Lab at UC Berkeley and has founded and serves on the scientific advisory boards of Caribou Biosciences, Inc. and Intellia Therapeutics, Inc., both leading CRISPR genome engineering companies. She was an Investigator with the Howard Hughes Medical Institute since 1997. Dr. Doudna is the recipient of numerous scientific awards in biochemistry and genetics, including the Alan T. Waterman Award the Eli Lilly Award in Biological Chemistry of the American Chemical Society a corecipient of the Breakthrough Prize in Life Sciences a corecipient of the Gruber Prize in Genetics a corecipient of the Canada Gairdner International Award the Heineken Prize for Biochemistry and Biophysics the Tang Prize the Japan Prize and the Albany Medical Center Prize . Dr. Doudna was elected to the National Academy of Sciences the American Academy of Arts and Sciences the National Academy of Medicine the National Academy of Inventors and as a Foreign Member of the Royal Society . Dr. Doudna is a Trustee for Pomona College. since 2018.
Age | 55 |
Tenure | 6 years |
Phone | 732 524 0400 |
Web | https://www.jnj.com |
Johnson Johnson Management Efficiency
The company has return on total asset (ROA) of 0.0881 % which means that it generated a profit of $0.0881 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2414 %, meaning that it generated $0.2414 on every $100 dollars invested by stockholders. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
James Heppner | United Airlines Holdings | 60 | |
Robert Coretz | Air Transport Services | 54 | |
Scott McGregor | Applied Materials | 61 | |
Ivan Donaldson | Micron Technology | N/A | |
Alfredo Torrado | Grupo Sports World | N/A | |
Daniel Quintanilla | GMxico Transportes SAB | 43 | |
Carlos Elizondo | Grupo Sports World | 44 | |
Maria Arnal | Grupo Sports World | N/A | |
Yvonne McGill | Applied Materials | N/A | |
David Vitale | United Airlines Holdings | 71 | |
Henry Meyer | United Airlines Holdings | 64 | |
Raymond Johns | Air Transport Services | 63 | |
Roberto Heredia | Grupo Sports World | N/A | |
Cynthia Ayon | Grupo Sports World | 52 | |
Edward Philip | United Airlines Holdings | 53 | |
Judy Bruner | Applied Materials | 59 | |
Richard Beyer | Micron Technology | 71 | |
Enrique HernandezPulido | Grupo Sports World | N/A | |
Arthur Lichte | Air Transport Services | 64 | |
James Whitehurst | United Airlines Holdings | 50 | |
Wilfrido Mejorada | Grupo Sports World | N/A |
Management Performance
Return On Equity | 0.24 | |||
Return On Asset | 0.0881 |
Johnson Johnson Leadership Team
Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
A Washington, Independent Director | ||
Dirk Brinckman, Chief Officer | ||
Jennifer Doudna, Independent Director | ||
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee | ||
William Perez, Independent Director | ||
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer | ||
Marillyn Hewson, Independent Director | ||
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer | ||
Mary Coleman, Independent Director | ||
Michael Ullmann, VP, General Counsel and Member of Executive Committee | ||
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals | ||
Joseph CPA, Ex CFO | ||
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals | ||
Mary Beckerle, Independent Director | ||
Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee | ||
Scott Davis, Director | ||
Louise Mehrotra, Vice President Investor Relations | ||
Robert Decker, Controller Officer | ||
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices | ||
Ronald Williams, Independent Director | ||
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
James Swanson, Ex Officer | ||
D Davis, Independent Director | ||
Hubert Joly, Independent Director | ||
Anne Mulcahy, Lead Independent Director | ||
Joseph Wolk, Chief Financial Officer, Executive Vice President | ||
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer | ||
Jessica Moore, VP Relations | ||
Ian Davis, Independent Director | ||
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee | ||
Mark McClellan, Independent Director | ||
Charles Prince, Independent Director | ||
Eugene Washington, Independent Director | ||
Elizabeth Forminard, Exec Counsel | ||
Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee | ||
Peter Fasolo, Chief Human Resource Officer, Executive Vice President | ||
Susan Lindquist, Independent Director | ||
Mark Weinberger, Independent Director |
Johnson Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.24 | |||
Return On Asset | 0.0881 | |||
Profit Margin | 0.19 % | |||
Operating Margin | 0.27 % | |||
Current Valuation | 9.15 T | |||
Shares Outstanding | 2.61 B | |||
Shares Owned By Insiders | 0.09 % | |||
Shares Owned By Institutions | 70.93 % | |||
Price To Earning | 28.71 X | |||
Price To Book | 6.26 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Johnson Stock please use our How to Invest in Johnson Johnson guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Johnson Stock analysis
When running Johnson Johnson's price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |